Evidence map›Paper›PMID 40462892›Full record

ArticlebioRxiv : the preprint server for biology2025

DRUG AND SINGLE-CELL GENE EXPRESSION INTEGRATION IDENTIFIES SENSITIVE AND RESISTANT GLIOBLASTOMA CELL POPULATIONS.

Robert K Suter, Anna M Jermakowicz, Rithvik Veeramachaneni, Matthew D'Antuono, Longwei Zhang, Rishika Chowdary, Simon Kaeppeli, Madison Sharp, Pravallika Palwai, Vasileios Stathias and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Robert K SuterDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0000-0002-3335-8426
Anna M JermakowiczDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0000-0003-3271-051X
Rithvik VeeramachaneniDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Matthew D'AntuonoDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0000-0002-1837-7004
Longwei ZhangDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0009-0007-1155-4171
Rishika ChowdaryDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0000-0002-9090-5916
Simon KaeppeliDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0000-0003-4449-6952
Madison SharpDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Pravallika PalwaiDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0009-0006-4750-6537
Vasileios StathiasDepartment of Molecular and Cellular Pharmacology, Institute for Data Science & Computing, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0003-1986-5947
Grace BakerDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Luz RuizDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0000-0001-6761-0899
Winston WaltersDepartment of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Maria CeperoDepartment of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
Danielle BurgenskeDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-0014-5579
Edward B ReillyAbbVie, Oncology Discovery, North Chicago, IL, USA.
Anatol OleksijewAbbVie, Oncology Discovery, North Chicago, IL, USA.
Mark G AndersonAbbVie, Oncology Discovery, North Chicago, IL, USA.
Sion Ll WilliamsSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-9426-3455
Michael E IvanSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-4798-4989
Ricardo J KomotarSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Macarena I De La FuenteSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Gregory SteinCurtana Pharmaceuticals, Inc, Austin, TX, USA.
Alexander WojcinskiPacific Neuroscience Institute and Saint John's Cancer Institute, Providence Health System, Santa Monica, CA, USA.
Santosh KesariPacific Neuroscience Institute and Saint John's Cancer Institute, Providence Health System, Santa Monica, CA, USA.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Stephan C SchürerDepartment of Molecular and Cellular Pharmacology, Institute for Data Science & Computing, University of Miami Miller School of Medicine, Miami, FL, USA.
Nagi G AyadDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0009-0002-1994-3095

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
Data Coordination and Integration Center for LINCS-BD2KU54HL127624 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MA'AYAN, AVI, SCHURER, STEPHAN C · 2014 to 2019
$23.5M
Targeting Cell-Type Specific Disease Phenotypes to Promote CNS RepairRM1NS133003 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI NAGI G AYAD, Jae K Lee · 2023 to 2026
$4.8M
NCI NIH HHS P30 CA240139NHLBI NIH HHS U54 HL127624NINDS NIH HHS RM1 NS133003
6 · The paper itself

Abstract

Glioblastoma (GBM) remains the most common and lethal adult malignant primary brain cancer with few treatment options. A significant issue hindering GBM therapeutic development is intratumor heterogeneity. GBM tumors contain neoplastic cells within a spectrum of different transcriptional states. Identifying effective therapeutics requires a platform that predicts the differential sensitivity and resistance of these states to various treatments. Here, we developed a novel framework, ISOSCELES (Inferred cell Sensitivity Operating on the integration of Single-Cell Expression and L1000 Expression Signatures), to quantify the cellular drug sensitivity and resistance landscape. Using single-cell RNA sequencing of newly diagnosed and recurrent GBM tumors, we identified compounds from the LINCS L1000 database with transcriptional response signatures selectively discordant with distinct GBM cell states. We validated the significance of these findings

Indexed as

Drug ResistanceGlioblastomaPharmacologyPharmacotranscriptomicsSingle-Cell RNA Sequencing

Identifiers

PMID40462892
PMCPMC12132552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.